Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P8PH
|
||||
| Former ID |
DIB021234
|
||||
| Drug Name |
XE991
|
||||
| Synonyms |
LS-190926
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H20N2O
|
||||
| InChI |
InChI=1S/C26H20N2O/c29-25-21-5-1-3-7-23(21)26(17-19-9-13-27-14-10-19,18-20-11-15-28-16-12-20)24-8-4-2-6-22(24)25/h1-16H,17-18H2
|
||||
| InChIKey |
KHJFBUUFMUBONL-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Kv7.5 | Target Info | Blocker (channel blocker) | [2] | |
| Potassium voltage-gated channel subfamily KQT member 4 | Target Info | Blocker (channel blocker) | [3] | ||
| Potassium voltage-gated channel subfamily KQT member 1 | Target Info | Blocker (channel blocker) | [4] | ||
| Potassium voltage-gated channel subfamily KQT member 2 | Target Info | Blocker (channel blocker) | [5] | ||
| KEGG Pathway | Cholinergic synapsehsa04261:Adrenergic signaling in cardiomyocytes | ||||
| Cholinergic synapse | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| Protein digestion and absorption | |||||
| Vibrio cholerae infectionhsa04725:Cholinergic synapse | |||||
| PANTHER Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Voltage gated Potassium channelsR-HSA-1296072:Voltage gated Potassium channelsR-HSA-1296072:Voltage gated Potassium channels | ||||
| Interaction between L1 and Ankyrins | |||||
| WikiPathways | Potassium ChannelsWP706:SIDS Susceptibility Pathways | ||||
| Potassium Channels | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| TarBasePathwayWP2669:Potassium Channels | |||||
| L1CAM interactions | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2596). | ||||
| REF 2 | KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000 Aug 4;275(31):24089-95. | ||||
| REF 3 | KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol. 2001 Apr;280(4):C859-66. | ||||
| REF 4 | Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23. | ||||
| REF 5 | KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998 Dec 4;282(5395):1890-3. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.